Drug Trial Radar · NCT05886088
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
597
Planned (sponsor's estimate)
Start
Feb 2024
Primary completion
May 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.
Conditions
- Type 2 Diabetes Mellitus
Interventions
LID104Drug
Experimental
DapagliflozinDrug
Active comparator
LinagliptinDrug
Active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glycated hemoglobin (HbA1c)Time frame: 120 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site
Hortolândia, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.